VAGUS NERVE STIMULATORS MARKET ANALYSIS

Vagus Nerve Stimulators Market Size and Trends

The vagus nerve stimulators market is estimated to be valued at USD 607.2 Mn in 2024 and is expected to reach USD 1,158.7 Mn by 2031, growing at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2031.

Discover market dynamics shaping the industry request sample copy

The market is expected to witness positive growth over the forecast period owing to the increasing prevalence of neurological disorders worldwide. Vagus nerve stimulation therapy has emerged as an effective treatment option for epilepsy and treatment-resistant depression. Further, ongoing technological advancements to develop innovative vagus nerve stimulator devices is also expected to support the market growth. For instance, companies are working on developing rechargeable and miniaturized vagus nerve stimulation devices to improve patient compliance. Thus, growing neurological disorder burden coupled with availability of advanced vagus nerve stimulator devices will collectively support the market expansion through 2031.

Rising prevalence of neurological disorders

The global vagus nerve stimulators market is expected to witness significant growth over the forecast period due to the rising prevalence of neurological disorders across the globe. Neurological disorders like epilepsy, depression, migraine, and Alzheimer's disease are imposing a huge impact on the physical and mental well-being of people as well as on healthcare systems. Vagus nerve stimulation (VNS) has emerged as an effective treatment option for drug-resistant epilepsy and treatment-resistant depression. Studies have shown that VNS is capable of reducing seizure frequency and severity in patients with uncontrolled epilepsy. It has also proven to be an effective therapy for treatment-resistant depression when conventional methods like pharmaceutical drugs fail to provide adequate relief. With increasing life expectancy and aging population globally, the prevalence of neurological conditions like Alzheimer's disease is also rising sharply. According to a World Health Organization (WHO) press release dated March 2023, more than 55 million people worldwide suffer from dementia, with more than 60% living in low- and middle-income nations. Every year, there are roughly 10 million new cases. Dementia is currently the seventh largest cause of death and one of the main causes of impairment and dependency in older people worldwide. The high prevalence of these neurological disorders has been contributing to the growing adoption of VNS therapy. This is likely to drive significant revenue generation opportunities for manufacturers of VNS devices in the future.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Get instant access to report

Reimbursement availability and policies play a crucial role in the growth of any medical device market. Favorable reimbursement for VNS therapy across major healthcare markets is creating a conducive environment for market expansion. In the U.S., VNS therapy is reimbursed by both public and private payers for epilepsy and depression indications. Major private insurers like UnitedHealthcare, Aetna, and Cigna provide coverage for the implantation procedure and generator replacement. Favorable reimbursement policies have encouraged larger patient uptake of this treatment option. Similarly in European countries, VNS systems are reimbursed for epilepsy under public health systems in countries like the U.K., Germany, France, and Italy. Governments in Asia Pacific countries are also taking initiatives to widen the insurance coverage for costly neurostimulation devices. Rising healthcare expenditure and reforms aimed at enhancing access to advanced treatments are expected to further strengthen the reimbursement scenario for VNS globally. This reimbursement predictability ensures a steady recurring demand for replacement generators, thereby supporting long term market growth prospects.

To learn more about this report, request sample copy

The vagus nerve stimulators market faces several challenges. Existing therapies have shown modest effectiveness and many patients do not achieve remission from symptoms. Research into new stimuli parameters and devices has proven difficult due to the complexity of the nervous system and limited understanding of vagus nerve's projection areas in the brain. The cost of devices and required surgical implantation also limits growth potential. Regulatory pathways for approval remain rigorous as these devices carry risks if not used as directed.

Market Opportunities: Rise in research and development activities

The prevalence of treatment-resistant depression and epilepsies targeted by VNS continues rising in developed nations. Ongoing technological advancements aim to minimize invasiveness and improve outcomes. Researchers are also exploring new indications for VNS therapy such as rheumatoid arthritis, heart rate regulation, and inflammatory disorders. With further data demonstrating efficacy, cost hurdles may gradually reduce through expanded reimburse thus, creating lucrative opportunities for market development over the forecasted period.

Discover high revenue pocket segments and roadmap to it: Get instant access to report

The product type segment includes implantable devices and external devices. Implantable devices segment is anticipated to hold 65.8% of the market share in 2024. Implantable devices offer longer-lasting treatment with minimal invasiveness compared to external devices. Advancements such as miniaturization of components and improved battery lives have increased patient comfort and compliance. Further, latest generation implantable devices allow wireless programming and data collection via external accessories like pads and wq1ands, eliminating the need for replacement surgery. This has boosted patient acceptance of implantable vagus nerve stimulators. Ongoing R&D focusing on programmable and customized stimulation parameters tailored for individual needs also support the growth of this segment. Leading manufacturers continuous investment in innovations like implant-able devices which can deliver different stimulation programs will drive segmental growth over the coming years.

Insights, By Application: Epilepsy Drives Adoption for Clinical Applications

The application segment includes epilepsy, depression & anxiety, migraine, and others. Epilepsy contributes the highest share of the vagus nerve stimulators market and is projected to hold 37.8% of the market share in 2024. Vagus nerve stimulation has been approved as an adjunctive therapy for epilepsy, especially for cases where seizure control cannot be achieved through medications. Clinical evidence showcasing the neurological benefits of vagus nerve stimulation in reducing seizure frequency and severity has led to increasing adoption among epileptic patients. Various mechanisms of action hypothesized indicate vagus nerve stimulation modulates central nervous system neurotransmitters released during seizure onset. It is also well-tolerated with relatively mild side effects, making it an attractive treatment option. Growing epilepsy prevalence globally will continue propelling the demand for vagus nerve stimulators targeting this clinical application segment.

Insights, By Material Type: Route of Administration Preference

The material type segment includes ceramics, metallics, and polymerics. Metallics contributes the highest share of the vagus nerve stimulators market and is projected to hold 41.2% of the market share in 2024. Metallic alloys like cobalt-chromium or titanium provide crucial attributes of corrosion resistance, biocompatibility, and mechanical strength required for implanted medical devices. They withstand harsh in-vivo environments without degradation or adverse tissue reactions over long implant durations. The electrically conductive property of metals enables precise stimulation delivery. Advances in microfabrication allow miniaturization of metallic components to less invasive dimensions. Strict regulatory protocols demand highest production standards which metallics can comply with. Therefore, metallic enclosures, leads and electrodes continue gaining preference over ceramics and polymers in commercial vagus nerve stimulator systems reaching the market. Emerging technologies involving metal 3D printing further support scaling up of customized metallic components.

Regional Insights

To learn more about this report, request sample copy

North America has established itself as the dominant region in the vagus nerve stimulators market and is projected to hold 42.8% of the market share in 2024. The presence of leading manufacturers such as LivaNova and electroCore in the U.S. has enabled the early adoption of vagus nerve stimulation devices in the region. Favorable reimbursement policies for conditions including epilepsy and depression have further increased access to these therapies. In addition, North America boasts higher healthcare expenditure compared to other global markets, allowing for growth in more complex neuromodulation treatments. Stringent regulatory standards and established clinical evidence have accelerated the approval and uptake of new vagus nerve stimulation systems. Major manufacturers have also focused their research and development efforts on the North America vagus nerve stimulators market, launching newer generations of devices with expanded indications. This has strengthened North America's position as an innovation hub, consolidating its leadership. With over a decade of recorded safety data, clinicians and patients in the region have grown increasingly confident in employing vagus nerve stimulation.

 Asia Pacific has emerged as the fastest growing regional market for vagus nerve stimulators. Countries such as China and Japan have witnessed a rapid increase in the incidence of neurological and psychiatric disorders in recent years due to aging populations and changing lifestyles. This has spurred government initiatives to boost accessibility and affordability of effective treatment solutions. The low infrastructure and labor costs have also encouraged global players to establish manufacturing bases in Asia Pacific to serve both local and export markets.

Market Report Scope

Vagus Nerve Stimulators Industry News

• On February 21, 2024, Tivic Health Systems, Inc., a health technology firm, announced that the enrollment in a pilot clinical study of a novel approach to non-invasive vagus nerve stimulation (VNS) is now complete. Implanted VNS is being utilized to treat a variety of neurologic and psychiatric disorders, and it is also being investigated in systemic inflammatory diseases. Tivic Health Systems, Inc. is developing a patented approach to more accurately regulate vagus nerve signals while improving effectiveness and safety through non-invasive treatment.
• On January 4, 2024, Pulsetto, a medical device company, announced that it will showcase its pioneering vagus nerve stimulation device at the Consumer Electronics Show, which took place in Las Vegas, U.S., from January 9 to 12, 2024. More than just a stress-relief tool, Pulsetto has a proven track record in helping improve sleep quality and facilitating overall body recovery. Its electric stimulation technique activates the vagus nerve in 4 minutes, making it one of the quickest ways to relax and unwind.
• In April 2023, MicroTransponder, Inc., a medical device firm, announced that the Vivistim Paired VNS System has earned the 2023 Gold Edison Award for being a game-changing product that enables stroke survivors to live more fulfilling lives. The Edison Awards recognize innovations that improve people's safety, health, and productivity.
• In August 2021, MicroTransponder, Inc. announced that the Vivistim Paired VNS System has received premarket approval from the U.S. Food and Drug Administration (FDA), which significantly improves the effectiveness of rehabilitation therapy for stroke survivors with moderate to severe upper extremity impairment six months after the stroke.

*Definition: The vagus nerve stimulators market comprises devices that are used to treat epilepsy and depression by delivering mild pulses of electrical energy to stimulate the vagus nerve. Vagus nerve stimulation therapy involves the use of a thin electrode lead placed around the left vagus nerve in the lower neck, connected to a pulse generator implanted under the skin near the collarbone. The generators send electrical pulses through the vagus nerve to the brain to help prevent seizures in people with epilepsy or help reduce symptoms in people with depression.

Market Segmentation

•  Product Type Insights (Revenue, USD MN, 2019 - 2031)
  • Implantable Devices
  • External Devices
•  Application Insights (Revenue, USD MN, 2019 - 2031)
  • Epilepsy
  • Depression & Anxiety
  • Migraine
  • Others
•  Material Type Insights (Revenue, USD MN, 2019 - 2031)
  • Ceramics
  • Metallics
  • Polymerics
•  End User Insights (Revenue, USD MN, 2019 - 2031)
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others
• Regional Insights (Revenue, USD MN, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • LivaNova PLC
  • electroCore Inc.
  • SetPoint Medical Corporation
  • Beijing PINS Medical Co. Ltd.
  • Parasym Ltd.
  • Nervana LLC
  • tVNS Technologies GmbH
  • BioControl Medical
  • NeurAxis Inc.
  • Soterix Medical Inc.
  • MicroTransponder Inc.
  • Boston Scientific Corporation
  • Cyberonics Inc.
  • EnteroMedics Inc.
  • ReShape Lifesciences Inc.
  • Cerbomed GmbH